Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 3/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30064999 | 1.00 | OPRM1 (0.44) | OPRM1OPRK1MEN1TSHRKMT2A | |
| SCHEMBL22208222 | 1.00 | OPRM1 (0.44) | OPRM1OPRK1MEN1TSHRKMT2A | |
| SCHEMBL22555109 | 1.00 | OPRM1 (0.44) | OPRM1OPRK1MEN1TSHRKMT2A | |
| SCHEMBL22555142 | 0.85 | PDK1 (0.47) | OPRM1OPRK1MEN1TSHRKMT2A | |
| SCHEMBL22555075 | 0.85 | PDK1 (0.47) | OPRM1OPRK1MEN1TSHRKMT2A | |
| SCHEMBL651151 | 0.82 | STS (0.47) | KMT2A | |
| SCHEMBL30071078 | 0.82 | STS (0.47) | KMT2A | |
| SCHEMBL929751 | 0.82 | STS (0.47) | KMT2A | |
| SCHEMBL29889592 | 0.79 | ABL1 (0.46) | OPRK1 | |
| SCHEMBL27816784 | 0.78 | BCHE (0.49) | MEN1TSHRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240109893-A1 | PREPARATION AND APPLICATION METHOD OF HETEROCYCLIC COMPOUNDS AS KRAS INHIBITOR | SHANGHAI KECHOW PHARMA, INC. (CN) | 2024-04-04 | — | — | US | disclosed |
| EP-4322945-A2 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2024-02-21 | — | — | EP | disclosed |
| EP-4269405-A1 | PREPARATION AND APPLICATION METHOD OF HETEROCYCLIC COMPOUND AS KRAS INHIBITOR | Shanghai Kechow Pharma, Inc. (CN) | 2023-11-01 | — | — | EP | disclosed |
| US-11548888-B2 | KRas G12C inhibitors | Mirati Therapeutics, Inc. (US) | 2023-01-10 | — | — | US | disclosed |
| WO-2022135470-A1 | PREPARATION AND APPLICATION METHOD OF HETEROCYCLIC COMPOUND AS KRAS INHIBITOR | 上海科州药物研发有限公司 | 2022-06-30 | — | — | WO | disclosed |
| US-20200331911-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. | 2020-10-22 | — | — | US | disclosed |
| US-20120208820-A1 | DIAZABICYCLIC CENTRAL NERVOUS SYSTEM ACTIVE AGENTS | SCHRIMPF MICHAEL R (US) | 2012-08-16 | — | — | US | disclosed |
| US-20100016277-A1 | DIAZABICYCLIC CENTRAL NERVOUS SYSTEM ACTIVE AGENTS | ABBOTT LABORATORIES (US) | 2010-01-21 | — | — | US | disclosed |
| US-7598236-B2 | Diazabicyclic central nervous system active agents | ABBOTT LABORATORIES (US) | 2009-10-06 | — | — | US | disclosed |
| US-20080097094-A1 | DIAZABICYCLIC CENTRAL NERVOUS SYSTEM ACTIVE AGENTS | ABBOTT LABORATORIES (US) | 2008-04-24 | — | — | US | disclosed |
| US-20080090798-A1 | Heterocyclic Substituted Aminoazacycles Useful as Central Nervous System Agents | ABBOTT LABORATORIES (US) | 2008-04-17 | — | — | US | disclosed |
| US-7332504-B2 | Heterocyclic substituted aminoazacycles useful as central nervous system agents | ABBOTT LABORATORIES (US) | 2008-02-19 | — | — | US | disclosed |
| US-7319106-B2 | Diazabicyclic central nervous system active agents | ABBOTT LABORATORIES (US) | 2008-01-15 | — | — | US | disclosed |
| US-20050043291-A1 | Heterocyclic substituted aminoazacycles useful as central nervous system agents | ABBVIE INC. | 2005-02-24 | — | — | US | disclosed |
| US-6833370-B1 | Selectively controlling neurotransmitter release; such as n-((3)-1-(6-chloro-3-pyridinyl)pyrrolidinyl)-n-methylamine | ABBOTT LABORATORIES | 2004-12-21 | — | — | US | disclosed |
| US-6809105-B2 | (CIS)-6-(3-PYRIDINYL)-3,6-DIAZABICYCLO(3.2.0) HEPTANE FOR EXAMPLE; ALZHEIMER'S DISEASE, PARKINSON'S DISEASE, ATTENTION DEFICIT HYPERACTIVITY DISORDER, DEPRESSION, NICOTINIC WITHDRAWAL SYNDROME, TOURETTE'S SYNDROME, AND SCHIZOPHRENIA | ABBOTT LABORATORIES | 2004-10-26 | — | — | US | disclosed |
| US-20040186107-A1 | Diazabicyclic central nervous system active agents | ABBVIE INC. | 2004-09-23 | — | — | US | disclosed |
| EP-1178982-B1 | HETEROCYCLIC SUBSTITUTED AMINOAZACYCLES USEFUL AS CENTRAL NERVOUS SYSTEM AGENTS | ABBOTT LAB (US) | 2004-06-30 | — | — | EP | disclosed |
| EP-1428824-A1 | Heterocyclic substituted aminoazacycles useful as central nervous system agents | ABBOTT LABORATORIES (US) | 2004-06-16 | — | — | EP | disclosed |
| US-20020019388-A1 | Diazabicyclic central nervous system active agents | ABBVIE INC. | 2002-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080097094-A1 | DIAZABICYCLIC CENTRAL NERVOUS SYSTEM ACTIVE AGENTS | GAP43, GABRE, CHRNA6 | OPRM1 190/4885OPRK1 219/4885MEN1 567/4885 |
| US-20120208820-A1 | DIAZABICYCLIC CENTRAL NERVOUS SYSTEM ACTIVE AGENTS | GAP43, GABRE, CHRNA6 | OPRM1 190/4885OPRK1 219/4885MEN1 567/4885 |
| US-11548888-B2 | KRas G12C inhibitors | KRAS, NRAS, HRAS | OPRM1 4750/4885OPRK1 4740/4885MEN1 348/4885 |
| US-20020019388-A1 | Diazabicyclic central nervous system active agents | GAP43, GABRE, CHRNA6 | OPRM1 166/4885OPRK1 192/4885MEN1 428/4885 |
| US-20240109893-A1 | PREPARATION AND APPLICATION METHOD OF HETEROCYCLIC COMPOUNDS AS KRAS INHIBITOR | KRAS, NRAS, HRAS | OPRM1 1986/4885OPRK1 1798/4885MEN1 1106/4885 |
| US-20100016277-A1 | DIAZABICYCLIC CENTRAL NERVOUS SYSTEM ACTIVE AGENTS | GAP43, GABRE, CHRNA6 | OPRM1 190/4885OPRK1 219/4885MEN1 567/4885 |
| US-20080090798-A1 | Heterocyclic Substituted Aminoazacycles Useful as Central Nervous System Agents | GRIN3A, GAP43, GRIN3B | OPRM1 89/4885OPRK1 86/4885MEN1 332/4885 |
| US-20200331911-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | OPRM1 4750/4885OPRK1 4740/4885MEN1 348/4885 |
| US-20040186107-A1 | Diazabicyclic central nervous system active agents | GAP43, GABRE, CHRNA6 | OPRM1 166/4885OPRK1 192/4885MEN1 428/4885 |
| US-20050043291-A1 | Heterocyclic substituted aminoazacycles useful as central nervous system agents | GRIN3A, GAP43, GRIN3B | OPRM1 89/4885OPRK1 86/4885MEN1 332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.